Editor Note: For more information about this release, please scroll to bottom.
LONDON, September 25, 2014 /PRNewswire/ --
On Wednesday, September 24, 2014, the NASDAQ Composite ended at 4,555.22, up 1.03%, the Dow Jones Industrial Average advanced 0.90%, to finish the day at 17,210.06, and the S&P 500 closed at 1,998.30, up 0.78%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 755.42, up 1.68%, with the index also advancing 7.83% in the previous three months. Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Merck and Company Inc. (NYSE: MRK), Johnson and Johnson (NYSE: JNJ), GlaxoSmithKline PLC (NYSE: GSK), and Bristol-Myers Squibb Company (NYSE: BMY). Free research on these five companies can be accessed at:
On Wednesday, shares in AbbVie Inc. traded between $57.61 and $59.35 before ending the session 2.59% higher at $59.05. The stock reported a trading volume of 15.61 million shares, above its three months average volume of 11.85 million shares. Shares of the company traded at a PE ratio of 20.06. AbbVie Inc.'s shares have advanced 6.97% in the last one month, 10.19% in the previous three months and 11.82% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $55.07 and $52.72, respectively. Moreover, shares of AbbVie Inc. have a Relative Strength Index (RSI) of 56.01. Sign up and read the free notes on ABBV at:
Merck and Co. Inc.'s stock edged 0.13% higher, to close the day at $60.36. The stock recorded a trading volume of 11.47 million shares, above its three months average volume of 8.27 million shares. The stock oscillated between $60.23 and $60.54 during the session. Over the last one month and over the past three months, Merck and Co. Inc.'s shares have gained 2.01% and 4.21%, respectively. Further, the stock has surged 20.60% since the start of this year. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $58.82 is above its 200-day moving average of $56.08. Additionally, Merck and Co. Inc. traded at a PE ratio of 16.83 and has an RSI of 55.38. The complimentary notes on MRK can be downloaded as in PDF format at:
On Wednesday, shares Johnson and Johnson recorded a trading volume of 5.89 million shares, lower than its three months average volume of 6.26 million shares. The stock ended the day at $108.64, which was 1.10% above its previous day's closing of $107.46, and registered an intraday range of $107.34 and $108.77. Shares of the company traded at a PE ratio of 18.62. Johnson and Johnson's shares have gained 5.37% in the last one month, 3.87% in the previous three months and 18.62% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $103.00 and $98.48, respectively. Furthermore, shares of Johnson and Johnson have an RSI of 69.49. Register for free on Investor-Edge and access the latest research on JNJ at:
GlaxoSmithKline PLC's stock edged 0.84% higher, to close Wednesday's session at $47.03, after oscillating between $46.59 and $47.04. The stock recorded a trading volume of 9.79 million shares, much above its three months average volume of 3.83 million shares. Over the previous three trading sessions and the last one month, GlaxoSmithKline PLC's shares have fallen by 0.74% and 1.36%, respectively. Additionally, from the beginning of 2014, the stock has declined 11.91%. The stock is trading below its 50-day and 200-day moving averages. The stock's 200-day moving average of $52.50 is above its 50-day moving average of $48.40. Further, GlaxoSmithKline PLC's stock has an RSI of 37.86. The complete research on GSK is available for free at:
Bristol-Myers Squibb Co.'s stock finished Wednesday's session 1.31% higher at $51.96. A total of 7.45 million shares were traded, which was above its three months average volume of 6.12 million shares. The stock moved between $51.33 and $52.11 during the session. Bristol-Myers Squibb Co.'s shares have advanced 3.55% in the last one month and 7.58% in the previous three months. However, the stock has lost 2.24% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $50.88 is greater than its 50-day moving average of $50.09. Bristol-Myers Squibb Co.'s stock traded at a PE ratio of 29.18 and has an RSI of 57.05. Free in depth research on BMY is available at:
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.